Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Revises FY 2003 Financial Targets

NEW YORK, Oct. 7 (GenomeWeb News) - Sequenom yesterday lowered its financial targets for the 2003 fiscal year, predicting total revenues of approximately $30 million for the calendar year and a year-end cash balance of $65 million.

In August, Sequenom CFO Steve Zaniboni told GenomeWeb News' sister publication SNPtech Reporter that the company's overall target revenue for the year was $34 million, with $32 million of that coming from its Systems unit. Yesterday, the company lowered that goal to $30 million, including $28.5 million from the Systems business unit. This amount reflects a growth rate of 15 percent over 2002 Systems business unit revenue of $24.8 million, the company said. 

Sequenom's annual revenue for the 2002 fiscal year was $30.9 million, and $30.7 million for fiscal year 2001.

Sequenom said it is expecting revenues for the third quarter to be approximately $7 million, including around $4 million in MassArray consumable sales. The company said this is a 75 percent increase from the same period last year.

Sequenom also lowered its projected 2003 year-end cash balance to around $65 million, from the $70 million to $75 million it predicted in April when it reported its first-quarter earnings.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.